Newton Charles W. — SEC Form 4 filings

SEC reporting owner CIK 1866219. 17 Form 4 filings on record with FilingPulse; latest filed 2026-08-20.

Transaction summary — filings shown

Covers all 17 filings on record, filed 2024-02-13 to 2026-08-20. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Lyell Immunopharma, Inc. (LYEL)Chief Financial Officer51 leg · 200,000 sh · $111,6203 legs · 1,720 sh · $18,1056
Keros Therapeutics, Inc. (KROS)Director32 legs · 1,101 sh · $11,1972
2seventy bio, Inc. (TSVT)Director38
NOVAVAX INC (NVAX)Director36
Coherus Oncology, Inc. (CHRS)Director34

Form 4 filings — Newton Charles W.

FiledFormIssuerReported transactionsSource
2026-08-204Keros Therapeutics, Inc. (KROS)Sale (S): 551 @ $10.30EDGAR
2026-06-234NOVAVAX INC (NVAX)Grant/award (A): 21,270 (derivative) @ $0 · Grant/award (A): 14,180 (derivative) @ $0EDGAR
2026-06-154Keros Therapeutics, Inc. (KROS)Sale (S): 550 @ $10.04EDGAR
2026-06-094Coherus Oncology, Inc. (CHRS)Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0EDGAR
2026-04-284NOVAVAX INC (NVAX)Option exercise (M): 9,520 @ $0 · Option exercise (M): 9,520 (derivative) @ $0EDGAR
2026-03-114Keros Therapeutics, Inc. (KROS)Grant/award (A): 13,215 @ $0 · Grant/award (A): 14,788 (derivative) @ $0EDGAR
2025-08-224Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 8,000 @ $0 · Sale (S): 1,453 @ $10.54EDGAR
2025-08-134Lyell Immunopharma, Inc. (LYEL)Sale (S): 131 @ $10.53 · Sale (S): 136 @ $10.34EDGAR
2025-06-134Coherus Oncology, Inc. (CHRS)Grant/award (A): 112,000 (derivative) @ $0EDGAR
2025-05-1542seventy bio, Inc. (TSVT)Disposition to issuer (D): 17,092 · Code (U): 5,533 · Disposition to issuer (D): 33,400 (derivative) · Disposition to issuer (D): 12,050 (derivative)EDGAR
2025-04-294NOVAVAX INC (NVAX)Grant/award (A): 42,840 (derivative) @ $0 · Grant/award (A): 28,560 (derivative) @ $0EDGAR
2025-03-184Lyell Immunopharma, Inc. (LYEL)Purchase (P): 200,000 @ $0.56EDGAR
2025-02-264Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 112,500 @ $0 · Grant/award (A): 450,000 (derivative) @ $0 · Grant/award (A): 56,250 (derivative) @ $0EDGAR
2024-06-1242seventy bio, Inc. (TSVT)Grant/award (A): 6,025 @ $0 · Grant/award (A): 12,050 (derivative) @ $0EDGAR
2024-06-054Coherus BioSciences, Inc. (CHRS)Grant/award (A): 112,000 (derivative) @ $0EDGAR
2024-03-2542seventy bio, Inc. (TSVT)Grant/award (A): 16,600 @ $0 · Grant/award (A): 33,400 (derivative) @ $0EDGAR
2024-02-134Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 40,000 @ $0 · Grant/award (A): 400,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1866219 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →